UBS Maintains Buy on Medline, Lowers Price Target to $43
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
UBS analyst Kevin Caliendo maintains Medline (NASDAQ:MDLN) with a Buy and lowers the price target from $45 to $43.
UBS analyst Kevin Caliendo maintains Medline (NASDAQ:MDLN) with a Buy and lowers the price target from $45 to $43.